Imatinib-associated hyperpigmentation, a side effect that should be recognized

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 1, 2009, Pages 82-83

  Mcpherson, T ^a   Sherman, V ^a   Turner, R ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ANAMNESIS; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; FEMALE; GUM HYPERPIGMENTATION; HUMAN; HYPERPIGMENTATION; LETTER; NAIL COLOR; NAIL COLOR DEFECT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PIGMENTATION DISORDERS; PIPERAZINES; PYRIMIDINES;

EID: 57649166233     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02706.x     Document Type: Letter

References (9)

1. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic phase chronic myeloid leukaemia. N Engl J Med 2003 348 : 994 1004.
2. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005 6 : 491 500.
3. Valeyrie L, Bastuji-Garin S, Revuz J et al. Adverse cutaneous reactions to imatinib (ST1-571) in Philadelphia chromosome positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003 48 : 201 206.
4. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003 98 : 2483 2487.
5. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukaemia patients treated with imatinib mesylate. Ann Oncol 2004 15 : 358 359.
6. Deguchi N, Kawamura T, Shimizu A et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. Br J Dermatol 2006 154 : 1216 1218.
7. Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007 56 : 460 465. Epub 2006 December 4.
8. Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukaemia. Indian J Dermatol Venereol Leprol 2006 72 : 63 64.
9. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005 16 : 1425 1433. Epub 2005 July 12.